Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant -Induced Lung Tumorigenesis

English version České info

KRAS mutant lung cancers are generally refractory to chemotherapy as well targeted agents. To date, the identification of drugs to therapeutically inhibit K-RAS have been unsuccessful, suggesting that other approaches are required. We demonstrate in both a novel transgenic mutant Kras lung cancer mouse model and in human lung tumors that the inhibition of Twist1 restores a senescence program inducing the loss of a neoplastic phenotype. The Twist1 gene encodes for a transcription factor that is essential during embryogenesis. Twist1 has been suggested to play an important role during tumor progression. However, there is no in vivo evidence that Twist1 plays a role in autochthonous tumorigenesis. Through two novel transgenic mouse models, we show that Twist1 cooperates with Kras^G12D to markedly accelerate lung tumorigenesis by abrogating cellular senescence programs and promoting the progression from benign adenomas to adenocarcinomas. Moreover, the suppression of Twist1 to physiological levels is sufficient to cause Kras mutant lung tumors to undergo senescence and lose their neoplastic features. Finally, we analyzed more than 500 human tumors to demonstrate that TWIST1 is frequently overexpressed in primary human lung tumors. The suppression of TWIST1 in human lung cancer cells also induced cellular senescence. Hence, TWIST1 is a critical regulator of cellular senescence programs, and the suppression of TWIST1 in human tumors may be an effective example of pro-senescence therapy.

Vyšlo v časopise: Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant -Induced Lung Tumorigenesis. PLoS Genet 8(5): e32767. doi:10.1371/journal.pgen.1002650
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002650

Souhrn

Zdroje

1. JemalASiegelRXuJWardE 2010 Cancer statistics, 2010. CA Cancer J Clin 60 277 300

2. DingLGetzGWheelerDAMardisERMcLellanMD 2008 Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455 1069 1075

3. FisherGHWellenSLKlimstraDLenczowskiJMTichelaarJW 2001 Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15 3249 3262

4. JiHLiDChenLShimamuraTKobayashiS 2006 The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 485 495

5. PolitiKZakowskiMFFanPDSchonfeldEAPaoW 2006 Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20 1496 1510

6. LiDShimamuraTJiHChenLHaringsmaHJ 2007 Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell 12 81 93

7. RegalesLBalakMNGongYPolitiKSawaiA 2007 Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2 e810 doi:10.1371/journal.pone.0000810

8. JankuFStewartDJKurzrockR 2010 Targeted therapy in non-small-cell lung cancer–is it becoming a reality? Nat Rev Clin Oncol 7 401 414

9. PaoWWangTYRielyGJMillerVAPanQ 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 e17 doi:10.1371/journal.pmed.0020017

10. EberhardDAJohnsonBEAmlerLCGoddardADHeldensSL 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 5900 5909

11. VerdineGLWalenskyLD 2007 The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 13 7264 7270

12. MesaRA 2006 Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther 6 313 319

13. JohnsonBEHeymachJV 2004 Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res 10 4254s 4257s

14. LuoJEmanueleMJLiDCreightonCJSchlabachMR 2009 A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137 835 848

15. SchollCFrohlingSDunnIFSchinzelACBarbieDA 2009 Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137 821 834

16. BarbieDATamayoPBoehmJSKimSYMoodySE 2009 Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 108 112

17. ColladoMSerranoM 2010 Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10 51 57

18. SerranoMLinAWMcCurrachMEBeachDLoweSW 1997 Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 593 602

19. LinHKChenZWangGNardellaCLeeSW 2010 Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464 374 379

20. PuyolMMartinADubusPMuleroFPizcuetaP 2010 A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18 63 73

21. SoucekLWhitfieldJMartinsCPFinchAJMurphyDJ 2008 Modelling Myc inhibition as a cancer therapy. Nature 455 679 683

22. ChenZFBehringerRR 1995 twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 9 686 699

23. AnsieauSBastidJDoreauAMorelAPBouchetBP 2008 Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14 79 89

24. LeeKEBar-SagiD 2010 Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 18 448 458

25. Entz-WerleNStoetzelCBerard-MarecPKalifaCBrugiereL 2005 Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer 117 349 355

26. HoekKRimmDLWilliamsKRZhaoHAriyanS 2004 Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64 5270 5282

27. KwokWKLingMTLeeTWLauTCZhouC 2005 Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65 5153 5162

28. MironchikYWinnardPTJrVesunaFKatoYWildesF 2005 Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65 10801 10809

29. OhuchidaKMizumotoKOhhashiSYamaguchiHKonomiH 2007 Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer 120 1634 1640

30. ZhangZXieDLiXWongYCXinD 2007 Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38 598 606

31. YangJManiSADonaherJLRamaswamySItzyksonRA 2004 Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 927 939

32. SmitMAPeeperDS 2008 Deregulating EMT and senescence: double impact by a single twist. Cancer Cell 14 5 7

33. LoewRVignaELindemannDNaldiniLBujardH 2006 Retroviral vectors containing Tet-controlled bidirectional transcription units for simultaneous regulation of two gene activities. Journal of Molecular and Genetic Medicine 2 107 118

34. PerlAKTichelaarJWWhitsettJA 2002 Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res 11 21 29

35. TranPTFanACBendapudiPKKohSKomatsubaraK 2008 Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. PLoS ONE 3 e2125 doi:10.1371/journal.pone.0002125

36. SubramanianATamayoPMoothaVKMukherjeeSEbertBL 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 15545 15550

37. JechlingerMGrunertSTamirIHJandaELudemannS 2003 Expression profiling of epithelial plasticity in tumor progression. Oncogene 22 7155 7169

38. Theilgaard-MonchKKnudsenSFollinPBorregaardN 2004 The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol 172 7684 7693

39. JiangYZhangWKondoKKlcoJMSt MartinTB 2003 Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1 453 462

40. CromerACarlesAMillonRGanguliGChalmelF 2004 Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23 2484 2498

41. MahlerJFStokesWMannPCTakaokaMMaronpotRR 1996 Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 24 710 716

42. NikitinAYAlcarazAAnverMRBronsonRTCardiffRD 2004 Classification of Proliferative Pulmonary Lesions of the Mouse: Recommendations of the Mouse Models of Human Cancers Consortium. Cancer Res 64 2307 2316

43. TuvesonDAShawATWillisNASilverDPJacksonEL 2004 Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 375 387

44. FeldserDMKostovaKKWinslowMMTaylorSECashmanC 2010 Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468 572 575

45. JunttilaMRKarnezisANGarciaDMadrilesFKortleverRM 2010 Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468 567 571

46. BeerDGKardiaSLHuangCCGiordanoTJLevinAM 2002 Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 816 824

47. BhattacharjeeARichardsWGStauntonJLiCMontiS 2001 Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98 13790 13795

48. LandiMTDrachevaTRotunnoMFigueroaJDLiuH 2008 Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 3 e1651 doi:10.1371/journal.pone.0001651

49. StearmanRSDwyer-NieldLZerbeLBlaineSAChanZ 2005 Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167 1763 1775

50. SuLJChangCWWuYCChenKCLinCJ 2007 Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 8 140

51. TalbotSGEstiloCMaghamiESarkariaISPhamDK 2005 Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res 65 3063 3071

52. WachiSYonedaKWuR 2005 Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21 4205 4208

53. SarkisianCJKeisterBAStairsDBBoxerRBMoodySE 2007 Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9 493 505

54. YoungNPJacksT Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A 107 10184 10189

55. JacksonELOliveKPTuvesonDABronsonRCrowleyD 2005 The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65 10280 10288

56. KwokWKLingMTYuenHFWongYCWangX 2007 Role of p14ARF in TWIST-mediated senescence in prostate epithelial cells. Carcinogenesis 28 2467 2475

57. StasinopoulosIAMironchikYRamanAWildesFWinnardPJr 2005 HOXA5-twist interaction alters p53 homeostasis in breast cancer cells. J Biol Chem 280 2294 2299

58. MaestroRDei TosAPHamamoriYKrasnokutskySSartorelliV 1999 Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13 2207 2217

59. Valsesia-WittmannSMagdeleineMDupasquierSGarinEJallasAC 2004 Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6 625 630

60. VichalkovskiAGreskoEHessDRestucciaDFHemmingsBA 2010 PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 29 3554 3565

61. ShiotaMIzumiHOnitsukaTMiyamotoNKashiwagiE 2008 Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene

62. YangMHHsuDSWangHWWangHJLanHY Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12 982 992

63. JangJWBoxerRBChodoshLA 2006 Isoform-specific Ras Activation and Oncogene Dependence in MYC and Wnt-induced Mammary Tumorigenesis. Mol Cell Biol

64. WuCHvan RiggelenJYetilAFanACBachireddyP 2007 Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A

65. VenturaAKirschDGMcLaughlinMETuvesonDAGrimmJ 2007 Restoration of p53 function leads to tumour regression in vivo. Nature

66. XueWZenderLMiethingCDickinsRAHernandoE 2007 Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature

67. NardellaCClohessyJGAlimontiAPandolfiPP 2011 Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11 503 511

68. PanDFujimotoMLopesAWangYX 2009 Twist-1 is a PPARdelta-inducible, negative-feedback regulator of PGC-1alpha in brown fat metabolism. Cell 137 73 86

69. SarinKYCheungPGilisonDLeeETennenRI 2005 Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436 1048 1052

70. NielsenCHKimuraRHWithofsNTranPTMiaoZ 2010 PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel 64Cu-DOTA-Knottin Peptide. Cancer Res 70 9022 9030